Cargando…
An Magnetic Resonance Imaging–directed Targeted-plus-perilesional Biopsy Approach for Prostate Cancer Diagnosis: “Less Is More”
BACKGROUND: Considering that most men benefit diagnostically from increased sampling of index lesions, limiting systematic biopsy (SBx) to the region around the index lesion could potentially minimize overdetection while maintaining the detection of clinically significant prostate cancer (csPCa). OB...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638771/ https://www.ncbi.nlm.nih.gov/pubmed/36353069 http://dx.doi.org/10.1016/j.euros.2022.07.006 |
_version_ | 1784825497452019712 |
---|---|
author | Hagens, Marinus J. Noordzij, M. Arjen Mazel, Jan Willem Jager, Auke Boellaard, Thierry N. Tielbeek, Jeroen A.W. Henebiens, Margot Schoots, Ivo G. van Leeuwen, Pim J. van der Poel, Henk G. Rynja, Sybren P. |
author_facet | Hagens, Marinus J. Noordzij, M. Arjen Mazel, Jan Willem Jager, Auke Boellaard, Thierry N. Tielbeek, Jeroen A.W. Henebiens, Margot Schoots, Ivo G. van Leeuwen, Pim J. van der Poel, Henk G. Rynja, Sybren P. |
author_sort | Hagens, Marinus J. |
collection | PubMed |
description | BACKGROUND: Considering that most men benefit diagnostically from increased sampling of index lesions, limiting systematic biopsy (SBx) to the region around the index lesion could potentially minimize overdetection while maintaining the detection of clinically significant prostate cancer (csPCa). OBJECTIVE: To evaluate the diagnostic performance of a hypothetical magnetic resonance imaging (MRI)-directed targeted-plus-perilesional biopsy approach. DESIGN, SETTING, AND PARTICIPANTS: This single-center, retrospective analysis of prospectively generated data included all biopsy-naïve men with unilateral MRI-positive lesions (Prostate Imaging Reporting and Data System category ≥3), undergoing both MRI-directed targeted biopsies and SBx. Grade group 2–5 cancers were considered csPCa. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The diagnostic performance of a targeted-plus-perilesional biopsy approach was compared with that of a targeted-plus-systematic biopsy approach. The primary outcome was the detection of csPCa. Secondary outcomes included the detection of clinically insignificant prostate cancer (ciPCa) and the number of total biopsy cores. RESULTS AND LIMITATIONS: A total of 235 men were included in the analysis; csPCa and ciPCa were detected, respectively, in 95 (40.4%) and 86 (36.6%) of these 235 men. A targeted-plus-perilesional biopsy approach would have detected 92/95 (96.8%; 95% confidence interval [CI] 91.0–99.3%) csPCa cases. At the same time, detection of systematically found ciPCa would be reduced by 11/86 (12.8%; 95% CI 6.6–21.7%). If a targeted-plus-perilesional biopsy approach would have been performed, the number of biopsy cores per patient would have been reduced significantly (a mean difference of 5.2; 95% CI 4.9–5.6, p < 0.001). CONCLUSIONS: An MRI-directed targeted-plus-perilesional biopsy approach detected almost all csPCa cases, while limiting overdiagnosis and reducing the number of biopsy cores. Prospective clinical trials are needed to substantiate the withholding of nonperilesional SBx in men with unilateral lesion(s) on MRI. PATIENT SUMMARY: Limiting systematic biopsies to the proximity of the suspicious area on magnetic resonance imaging helps detect an equivalent number of aggressive cancers and fewer indolent cancers. These findings may help patients and physicians choose the best biopsy approach. |
format | Online Article Text |
id | pubmed-9638771 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-96387712022-11-08 An Magnetic Resonance Imaging–directed Targeted-plus-perilesional Biopsy Approach for Prostate Cancer Diagnosis: “Less Is More” Hagens, Marinus J. Noordzij, M. Arjen Mazel, Jan Willem Jager, Auke Boellaard, Thierry N. Tielbeek, Jeroen A.W. Henebiens, Margot Schoots, Ivo G. van Leeuwen, Pim J. van der Poel, Henk G. Rynja, Sybren P. Eur Urol Open Sci Prostate Cancer BACKGROUND: Considering that most men benefit diagnostically from increased sampling of index lesions, limiting systematic biopsy (SBx) to the region around the index lesion could potentially minimize overdetection while maintaining the detection of clinically significant prostate cancer (csPCa). OBJECTIVE: To evaluate the diagnostic performance of a hypothetical magnetic resonance imaging (MRI)-directed targeted-plus-perilesional biopsy approach. DESIGN, SETTING, AND PARTICIPANTS: This single-center, retrospective analysis of prospectively generated data included all biopsy-naïve men with unilateral MRI-positive lesions (Prostate Imaging Reporting and Data System category ≥3), undergoing both MRI-directed targeted biopsies and SBx. Grade group 2–5 cancers were considered csPCa. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The diagnostic performance of a targeted-plus-perilesional biopsy approach was compared with that of a targeted-plus-systematic biopsy approach. The primary outcome was the detection of csPCa. Secondary outcomes included the detection of clinically insignificant prostate cancer (ciPCa) and the number of total biopsy cores. RESULTS AND LIMITATIONS: A total of 235 men were included in the analysis; csPCa and ciPCa were detected, respectively, in 95 (40.4%) and 86 (36.6%) of these 235 men. A targeted-plus-perilesional biopsy approach would have detected 92/95 (96.8%; 95% confidence interval [CI] 91.0–99.3%) csPCa cases. At the same time, detection of systematically found ciPCa would be reduced by 11/86 (12.8%; 95% CI 6.6–21.7%). If a targeted-plus-perilesional biopsy approach would have been performed, the number of biopsy cores per patient would have been reduced significantly (a mean difference of 5.2; 95% CI 4.9–5.6, p < 0.001). CONCLUSIONS: An MRI-directed targeted-plus-perilesional biopsy approach detected almost all csPCa cases, while limiting overdiagnosis and reducing the number of biopsy cores. Prospective clinical trials are needed to substantiate the withholding of nonperilesional SBx in men with unilateral lesion(s) on MRI. PATIENT SUMMARY: Limiting systematic biopsies to the proximity of the suspicious area on magnetic resonance imaging helps detect an equivalent number of aggressive cancers and fewer indolent cancers. These findings may help patients and physicians choose the best biopsy approach. Elsevier 2022-08-02 /pmc/articles/PMC9638771/ /pubmed/36353069 http://dx.doi.org/10.1016/j.euros.2022.07.006 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Prostate Cancer Hagens, Marinus J. Noordzij, M. Arjen Mazel, Jan Willem Jager, Auke Boellaard, Thierry N. Tielbeek, Jeroen A.W. Henebiens, Margot Schoots, Ivo G. van Leeuwen, Pim J. van der Poel, Henk G. Rynja, Sybren P. An Magnetic Resonance Imaging–directed Targeted-plus-perilesional Biopsy Approach for Prostate Cancer Diagnosis: “Less Is More” |
title | An Magnetic Resonance Imaging–directed Targeted-plus-perilesional Biopsy Approach for Prostate Cancer Diagnosis: “Less Is More” |
title_full | An Magnetic Resonance Imaging–directed Targeted-plus-perilesional Biopsy Approach for Prostate Cancer Diagnosis: “Less Is More” |
title_fullStr | An Magnetic Resonance Imaging–directed Targeted-plus-perilesional Biopsy Approach for Prostate Cancer Diagnosis: “Less Is More” |
title_full_unstemmed | An Magnetic Resonance Imaging–directed Targeted-plus-perilesional Biopsy Approach for Prostate Cancer Diagnosis: “Less Is More” |
title_short | An Magnetic Resonance Imaging–directed Targeted-plus-perilesional Biopsy Approach for Prostate Cancer Diagnosis: “Less Is More” |
title_sort | magnetic resonance imaging–directed targeted-plus-perilesional biopsy approach for prostate cancer diagnosis: “less is more” |
topic | Prostate Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638771/ https://www.ncbi.nlm.nih.gov/pubmed/36353069 http://dx.doi.org/10.1016/j.euros.2022.07.006 |
work_keys_str_mv | AT hagensmarinusj anmagneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore AT noordzijmarjen anmagneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore AT mazeljanwillem anmagneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore AT jagerauke anmagneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore AT boellaardthierryn anmagneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore AT tielbeekjeroenaw anmagneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore AT henebiensmargot anmagneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore AT schootsivog anmagneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore AT vanleeuwenpimj anmagneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore AT vanderpoelhenkg anmagneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore AT rynjasybrenp anmagneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore AT hagensmarinusj magneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore AT noordzijmarjen magneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore AT mazeljanwillem magneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore AT jagerauke magneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore AT boellaardthierryn magneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore AT tielbeekjeroenaw magneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore AT henebiensmargot magneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore AT schootsivog magneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore AT vanleeuwenpimj magneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore AT vanderpoelhenkg magneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore AT rynjasybrenp magneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore |